UK-based Oxford BioMedica has signed a new collaboration and licence agreement with Bioverativ for the development and manufacture of lentiviral vectors to treat haemophilia.

The agreement will see an upfront payment of $5m by Bioverativ to Oxford BioMedica, which is also eligible for an additional $100m in different milestone-based payments.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Oxford BioMedica will also receive net sales royalties on Bioverativ’s lentiviral vector haemophilia products.

Oxford BioMedica CEO John Dawson said: “Bioverativ’s investment in haemophilia gene therapy underlines the potential of lentiviral vectors for use for in-vivo gene therapy.

“This new deal, potentially worth in excess of $100m, demonstrates Oxford BioMedica’s strategy of building multiple partnerships with leaders in their therapeutic categories and will support the group’s continued growth.”

“Bioverativ’s investment in haemophilia gene therapy underlines the potential of lentiviral vectors for use for in vivo gene therapy.”

The agreement also involves a licence to leverage Oxford BioMedica’s LentiVector Enabled technology, as well as access to the firm’s industrial-scale manufacturing technology.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Designed as an advanced lentiviral-based gene delivery system, the LentiVector platform has applications in various therapeutic areas. It can genetically modify dividing and non-dividing cells, and insert genes into non-dividing cells.

The platform also acts as a research tool with uses in stem cell manipulation, transgenesis, somatic disease models, target validation and gene discovery.

Bioverativ will sponsor the activities associated with the process development and scale-up of its lentiviral vector haemophilia products at Oxford BioMedica.

In addition, the agreement includes an option to negotiate a clinical supply agreement for GMP manufacturing of these products at the company.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact